<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vir Biotechnology Inc — News on 6ix</title>
<link>https://6ix.com/company/vir-biotechnology-inc</link>
<description>Latest news and press releases for Vir Biotechnology Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vir-biotechnology-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d27278dffbe2df12023e.webp</url>
<title>Vir Biotechnology Inc</title>
<link>https://6ix.com/company/vir-biotechnology-inc</link>
</image>
<item>
<title>Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-to-host-conference-call-for-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-to-host-conference-call-for-first-quarter-2026-financial-results</guid>
<pubDate>Thu, 23 Apr 2026 20:05:00 GMT</pubDate>
<description>SAN FRANCISCO, April 23, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.</description>
</item>
<item>
<title>Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-closing-of-global-strategic-collaboration-with-astellas-for-the-treatment-of-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-closing-of-global-strategic-collaboration-with-astellas-for-the-treatment-of-prostate-cancer</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - Astellas to lead commercialization</description>
</item>
<item>
<title>Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-first-patient-dosed-in-phase-1-dose-expansion-cohorts-evaluating-psma-targeted-pro-xtenr-dual-masked-t-cell-engager-vir-5500-in-patients-with-metastatic-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-first-patient-dosed-in-phase-1-dose-expansion-cohorts-evaluating-psma-targeted-pro-xtenr-dual-masked-t-cell-engager-vir-5500-in-patients-with-metastatic-prostate-cancer</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>Phase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in both early and late-line metastatic</description>
</item>
<item>
<title>Vir Biotechnology to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following</description>
</item>
<item>
<title>Vir Biotechnology Announces Pricing of Public Offering of Common Stock</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-pricing-of-public-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-pricing-of-public-offering-of-common-stock</guid>
<pubDate>Thu, 26 Feb 2026 03:31:00 GMT</pubDate>
<description>SAN FRANCISCO, February 26, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 17,647,058 shares of its common stock at a price to the public of $8.50 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, be</description>
</item>
<item>
<title>Vir Biotechnology Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-proposed-public-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-proposed-public-offering-of-common-stock</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN FRANCISCO, February 24, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer $200,000,000 of shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,00</description>
</item>
<item>
<title>Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-reports-positive-updated-phase-1-results-for-psma-targeting-pro-xtenr-dual-masked-t-cell-engager-vir-5500-in-patients-with-metastatic-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-reports-positive-updated-phase-1-results-for-psma-targeting-pro-xtenr-dual-masked-t-cell-engager-vir-5500-in-patients-with-metastatic-prostate-cancer</guid>
<pubDate>Mon, 23 Feb 2026 22:02:00 GMT</pubDate>
<description>SAN FRANCISCO, February 23, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN® dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy (NCT05997615). These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising a</description>
</item>
<item>
<title>Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO, March 26, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and</description>
</item>
<item>
<title>Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xtenr-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xtenr-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues -- Astellas to lead commercialization</description>
</item>
<item>
<title>Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-host-conference-call-210500241</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-host-conference-call-210500241</guid>
<pubDate>Mon, 09 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN FRANCISCO, February 09, 2026--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate update and discuss its financial results for the fourth quarter and full year ended December 31, 2025. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.</description>
</item>
<item>
<title>Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-provides-updates-chronic-hepatitis-delta-and-oncology-programs-and</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-provides-updates-chronic-hepatitis-delta-and-oncology-programs-and</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>– Positive, updated Phase 2 SOLSTICE data showed combination of tobevibart and elebsiran is well tolerated and achieved undetectable HDV RNA in 88% of</description>
</item>
<item>
<title>Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer,</description>
</item>
<item>
<title>Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/norgine-enhances-hepatology-and-specialty-portfolio-through-exclusive-in-licensing-agreement-with-vir-biotechnology</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/norgine-enhances-hepatology-and-specialty-portfolio-through-exclusive-in-licensing-agreement-with-vir-biotechnology</guid>
<pubDate>Wed, 17 Dec 2025 08:01:00 GMT</pubDate>
<description>Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialise the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) in Europe, Australia and New Zealand following the necessary marketing authorisations. There is a high unmet medical need for effective treatments for CHD given potential limitations with existing treatment options.</description>
</item>
<item>
<title>Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-grants-norgine-exclusive-commercial-license-chronic-hepatitis-delta</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-grants-norgine-exclusive-commercial-license-chronic-hepatitis-delta</guid>
<pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
<description>– Vir Biotechnology to receive EUR 55 million initial reimbursement payment upon closing, and up to EUR 495 million in clinical, regulatory and sales</description>
</item>
<item>
<title>Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-participate-8th-annual-evercore-healthcare-conference-2025-11-19</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-participate-8th-annual-evercore-healthcare-conference-2025-11-19</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer,</description>
</item>
<item>
<title>Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-aasld-liver-meetingr-presentation-new-england-journal</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-aasld-liver-meetingr-presentation-new-england-journal</guid>
<pubDate>Sun, 09 Nov 2025 05:00:00 GMT</pubDate>
<description>SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable</description>
</item>
<item>
<title>Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-participate-jefferies-2025-london-healthcare-conference-2025-11-07</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-participate-jefferies-2025-london-healthcare-conference-2025-11-07</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer,</description>
</item>
<item>
<title>Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-provides-corporate-update-and-reports-third-quarter-2025-financial</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-provides-corporate-update-and-reports-third-quarter-2025-financial</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>- ECLIPSE 1 enrollment completed approximately two months ahead of schedule; ECLIPSE 2 and ECLIPSE 3 progressing with strong enrollment momentum, with</description>
</item>
<item>
<title>Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-completion-enrollment-eclipse-1-phase-3-trial-chronic</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-announces-completion-enrollment-eclipse-1-phase-3-trial-chronic</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>– ECLIPSE 1 estimated date of last participant reaching primary endpoint (primary completion) in the fourth quarter of 2026, and topline data expected in the</description>
</item>
<item>
<title>Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025</title>
<link>https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-provide-corporate-update-and-report-third-quarter-2025-financial</link>
<guid isPermaLink="true">https://6ix.com/company/vir-biotechnology-inc/news/vir-biotechnology-provide-corporate-update-and-report-third-quarter-2025-financial</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial</description>
</item>
</channel>
</rss>